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A B S T R A C T
The transmission-blocking vaccine candidate Pfs48/45 from the human malaria parasite Plasmodium falciparum
is known to be diﬃcult to express in heterologous systems, either as full-length protein or as correctly folded
protein fragments that retain conformational epitopes. In this study we express full-length Pfs48/45 in the rodent
parasite P. berghei. Pfs48/45 is expressed as a transgene under control of the strong P. berghei schizont-speciﬁc
msp1 gene promoter (Pfs48/45@PbMSP1). Pfs48/45@PbMSP1 schizont-infected red blood cells produced full-
length Pfs48/45 and the structural integrity of Pfs48/45 was conﬁrmed using a panel of conformation-speciﬁc
monoclonal antibodies that bind to diﬀerent Pfs48/45 epitopes. Sera from mice immunized with transgenic
Pfs48/45@PbMSP1 schizonts showed strong transmission-reducing activity in mosquitoes infected with P. fal-
ciparum using standard membrane feeding. These results demonstrate that transgenic rodent malaria parasites
expressing human malaria antigens may be used as means to evaluate immunogenicity and functionality of
diﬃcult to express malaria vaccine candidate antigens.
1. Introduction
Eﬃcient and conformationally-accurate expression of Plasmodium
proteins in heterologous systems, such as yeast or bacteria, is frequently
problematic resulting in misfolded or incorrectly modiﬁed proteins,
which are often poorly expressed [1,2]. This hampers the screening of
Plasmodium antigens in immunization studies for their suitability as
vaccine candidate antigens. Preclinical evaluation of Plasmodium anti-
gens often involves immunizing rodents with recombinant Plasmodium
proteins followed by an examination of induced immune responses,
either in vivo using rodent models of malaria or in vitro by performing
functional assays with human malaria parasites incubated with immune
sera [3]. Multiple factors contribute to ineﬃcient expression of Plas-
modium proteins, such as the high AT content of Plasmodium genes,
large size and often unique protein structure (i.e. encoding repeated
stretches of amino acids) and unique post-translational modiﬁcations
[1,4]. This is particularly evident for cysteine-rich proteins where cor-
rect folding depends on accurate formation of disulﬁde bridges to form
domains speciﬁc for Plasmodium proteins [5–7]. Transgenic rodent
malaria parasites (RMP) expressing human malaria parasite (HMP)
proteins are increasingly used to evaluate and rank order candidate
malaria vaccines before investing in scalable manufacture to support
advancement to clinical testing [3]. Such transgenic RMP have been
used in preclinical assays to evaluate vaccine potential of HMP proteins,
both in vivo where mice are immunized with HMP antigens and sub-
sequently challenged with transgenic RMP expressing the cognate HMP
or in in vitro assays where immune sera or antibodies are evaluated for
inhibition of parasite growth or invasion. Both the functional com-
plementation of RMP genes by the HMP orthologs [3] and analysis of
HMP expression using antisera, provide evidence for correct expression
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of functional HMP proteins in transgenic RMP [8]. Based on these
studies, we reasoned that transgenic RMP can be used as expression
systems to more eﬃciently express, screen, validate and down-select
HMP antigens as potential novel malaria vaccine candidates [2,9].
Further, the expression of conformationally-accurate Plasmodium pro-
teins could be used to generate epitope-speciﬁc monoclonal antibodies,
which in turn can be used to better characterize the vaccine antigen.
The use of RMP would circumvent many of the above-mentioned pro-
blems associated with expression in heterologous expression systems
including, but not limited to, peculiarities of post-translational mod-
iﬁcations and Plasmodium-speciﬁc domains involved in protein traf-
ﬁcking and cellular location. As a proof of concept, we generated
transgenic P. berghei (Pb) parasites that express full length Pfs48/45
from P. falciparum (Pf). The Pfs48/45 protein is expressed in
(caption on next page)
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Plasmodium gametocytes and gametes [10,11] and contains multiple
cysteine-rich domains with multiple disulﬁde bonds [12–14]. These
constitute distinct conformational B cell epitopes that can be recognized
by several monoclonal antibodies some of which have transmission-
blocking (TB) activity [15]. Pfs48/45 becomes exposed on the surface
of gametes once the parasite is taken up in blood meal by a mosquito
and here the antigen can be targeted by antibodies and other compo-
nents of the blood meal [16]. Expression of Pfs48/45 for TB im-
munization studies has been problematic in most commonly used ex-
pression systems, mainly due to incorrect or insuﬃcient protein folding,
which is dependent on the correct formation of disulﬁde bridges in this
cysteine-rich protein [17,18]. The limited reactivity of recombinant
Pfs48/45 with monoclonal antibodies against conformational epitopes
of Pfs48/45 has indicated this misfolding [19,20].
2. Results and discussion
In this study the coding sequence of the gene encoding Pfs48/45
(PF3D7_1346700) was introduced into the redundant P. berghei p230p
gene locus (PBANKA_0306000) [3,21,22]. The Pfs48/45 gene was
placed under control of 1.3 kb of the promoter region of the schizont-
speciﬁc Pb msp1 gene (PBANKA_0831000). This promoter was chosen
since msp1 is one of the highest transcribed genes in developing Pb
schizonts [23] and the Pb schizont stage can be easily produced and
puriﬁed in large quantities [24]. The transgenic parasite (Pfs48/45@
PbMSP1) was generated by the method of GIMO transfection and se-
lection [21]. Using this method transgenes can be rapidly introduced
into the p230p gene locus in a GIMOpbANKA parent line by replacing the
positive-negative selectable marker expression cassette by the trans-
gene expression cassette (Supplementary M&M and Fig. 1A). Correct
replacement of the selectable marker cassette and insertion of the
Pfs48/45 expression cassette in a cloned line of Pfs48/45@PbMSP1
(1807cl2) was conﬁrmed by diagnostic PCR and Southern analysis of
chromosomes separated by pulsed-ﬁeld gel electrophoresis (Fig. 1B).
Analysis of the growth rate of transgenic Pfs48/45@PbMSP1 parasites
during the cloning period demonstrated normal growth of blood stages,
comparable to wild type (WT) PbANKA parasites (i.e. all mice (n= 3)
achieved a 0.5–2% parasitemia on day 8, after inoculation with a single
infected red blood cell). To obtain transgenic schizonts, parasites were
cultured overnight using standard methods to produce and purify Pb
schizonts (Supplementary M&M).
We conﬁrmed expression of Pfs48/45 in the transgenic schizonts by
Western and immuno-ﬂuorescence analysis using four anti-Pfs48/45
monoclonal antibodies 85RF45.1 (45.1), 85RF45.2b (45.2b), 85RF45.3
(45.3), and 85RF45.5 (45.5). Three of these (45.1, 45.2b and 45.3)
recognize conformational epitopes (epitopes I, IIb and III respectively)
in the C terminal region of Pfs48/45 [14].
In Western analysis all the antibodies recognize a protein of the
expected size (48 kDa) in
protein extracts from Pfs48/45@PbMSP1 schizonts and WT Pf ga-
metocytes but not in extracts from a Pb line that does not express Pfs48/
45 (i.e. GIMOpbANKA line 1596cl1). As a positive control, recombinant
protein that contains a fragment of P. falciparum Pfs48/45 fused to the
GLURP R0 domain (R0.10C) was included and as expected a 150 kDa
band was present after probing with monoclonal antibodies 45.1, 45.2b
and 45.3 but was not present after probing with 45.5 (Fig. 1C) [25]. We
next examined the presence of Pfs48/45 epitopes using the anti-Pfs48/
45 antibodies by immuno-ﬂuorescence assay (IFA) (Fig. 1D). All anti-
bodies recognized Pfs48/45 produced in the Pfs48/45@PbMSP1 schi-
zonts and did not react with proteins of WT Pb schizonts (Fig. 1C and
1D). These results demonstrate that transgenic Pb schizonts can eﬀec-
tively express full length Pfs48/45, which retains a number of con-
formational epitopes. Pfs48/45, like MSP1, contains a GPI anchor and is
present at the plasma membrane of Pf gametocytes/gametes [26]. The
immuno-ﬂuorescence analyses indicate that Pfs48/45 was located in
the cytoplasm of the transgenic merozoites as the ﬂuorescence signals
did not completely overlap with ﬂuorescence signals obtained with
anti-MSP1 antibodies, which stain MSP1 at the merozoite plasma
membrane in mature schizonts (Fig. 1D). Possible reasons for this ob-
servation is that GPI attachment may be diﬀerent between rodent and
human Plasmodium parasites, or that the attachment of Pfs48/45 onto
P. berghei merozoites would require the presence of other Plasmodium
proteins normally present in gametocytes/gametes.
In order to estimate the proportion of Pfs48/45 present in the pro-
tein lysates of Pfs48/45@PbMSP1 schizonts we performed a quantita-
tive Western Blot analysis. Densitometry analysis of signals obtained
after probing known amounts of Pfs48/45@PbMSP1 protein schizont
lysates and a dilution series of recombinant Pfs48/45 with anti-Pfs48/
45 monoclonal 45.1, revealed that the intensity of the schizont lysate
signals corresponds to less than 1 ng of recombinant Pfs48/45
(Supplementary Fig. S1), indicating that is between 0.25 - 0.12% of
the total schizont lysate is Pfs48/45 (Fig. 2A).
Next, we examined if Pfs48/45@PbMSP1 transgenic schizont lysate
could be used to raise sera that could block Pf transmission in mos-
quitoes, presumably by Pfs48/45 speciﬁc antibodies. Two groups of 10
C57BL/6 mice were immunized 4 times (2 week interval) with lysates
of 1×108 schizonts of either Pfs48/45@PbMSP1 or WT (c15cy1)
parasites (Fig. 2B). Puriﬁed schizonts were inactivated by three rounds
of freezing on dry ice followed by thawing at room temperature before
immunization and schizont lysates were injected intravenously. Two
Fig. 1. Generation, genotype and phenotype analyses of Pfs48/45@PbMSP1, a transgenic P. berghei parasite expressing P. falciparum P48/45 in schizonts.
(A) Schematic representation of the introduction of the Pfs48/45-expression cassette into the GIMOpbANKA parasite (line 1596cl1). Construct pL1707 contains the
Pfs48/45 gene ﬂanked by the msp1 promoter region and the 3′ pbdhfr UTR. This construct is integrated into the modiﬁed P. berghei 230p locus of GIMOpbANKA that
contains the hdhfr::yfcu selectable marker (SM) cassette by double cross-over homologous recombination at the homology regions (230p; grey boxes). Negative
selection with 5-FC selects for parasites that have the SM cassette replaced by the Pfs48/45 expression cassette. Location of primers used for PCR analysis and sizes of
PCR products are shown.
(B) Diagnostic PCR (upper panel) and Southern analysis of PFG-separated chromosomes (lower panel) conﬁrm correct integration of construct pL1707 in line
1807cl2 parasites. PCR shows the absence of the hdhfr::yfcumarker and the presence of the Pfs48/45. 5′ integration PCR (5′ int; primers p5/p6), 3′ integration PCR (3′
int; primers p7/p8), hdhfr::yfcu (primers p1/p2), Pfs48/45 (primers p3/p4). Primer locations and product sizes are shown in A and primer sequences in Table S1).
Hybridization of PFG-separated chromosomes with a mixture of two probes (the hdhfr probe and a control probe recognizing p25 gene on chromosome 5) shows the
removal of the SM cassette marker in the 230p locus on chromosome 3 in 1807cl2 parasites.
(C)Western analysis of Pfs48/45 expression in protein extracts of puriﬁed gametocytes of P. falciparum (Pf Gam), puriﬁed schizonts of wild type P. berghei (1596cl1)
and puriﬁed schizonts of Pfs48/45@PbMSP1 (1807cl2). As a positive control, recombinant P. falciparum P48/45 fragment fused to GLURP R0 domain (R0.10C) was
included (expected molecular size is 150 kDa). Blots were stained with 4 diﬀerent anti-Pfs48/45 antibodies (45.1-3, 45.5) that recognize diﬀerent epitopes. Anti-
PyMSP1 antibody staining was used as a loading control.
(D) Immuno-ﬂuorescence analyses of Pfs48/45 expression in puriﬁed schizonts of Pfs48/45@PbMSP1 (1807cl2), and the reference parent P. berghei GIMO line (i.e.
WT; 1596cl1). Fixed parasites were stained with four diﬀerent rat anti-Pfs48/45 mAbs (45.1-3, 45.5) and rabbit anti-PyMSP1 antibody followed by secondary
conjugated antibodies anti-rabbit IgG Alexa Fluor ® 488 (green) or anti-rat IgG Alexa Fluor ® 594 (red). Nuclei stained with the DNA-speciﬁc dye Hoechst 33,342 (H).
All pictures were recorded with the same exposure/gain times; anti-rabbit IgG Alexa Fluor ® 488 (green) 0.7 s; anti-rat IgG Alexa Fluor ® 594 (red) 0.6 s; Hoechst
(blue) 0.136 s; bright ﬁeld 0.62 s (1x gain). BF: bright ﬁeld; M: merged. Scale bar: 2 μm.
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weeks after the ﬁnal immunization, serum was collected from all ani-
mals and a serum pool made for each group. Total IgG was isolated
from the pooled sera and tested for transmission-reducing activity (TR
activity) in standard membrane feeding assays (SMFA) using Pf game-
tocytes (Supplementary M&M). Pf gametocytes were fed to A. stephensi
mosquitoes in the presence of IgG obtained from mice immunized with
schizonts of either Pfs48/45@PbMSP1 or WT. In the ﬁrst experiment,
IgG (1500 μg/ml) from Pfs48/45@PbMSP1-immunized mice showed
99.8% inhibition in oocyst density (p=0.001) compared to the IgG
obtained from WT immunized (Fig. 2C). Next, TR activity was de-
termined in SMFA using a dilution series of the IgG obtained from
Pfs48/45@PbMSP1-immunized mice. Signiﬁcant TR activity with IgG
from Pfs48/45@PbMSP1-immunized mice was still observed at a con-
centration of 187 μg/ml (p= 0.014) compared to the control IgG
(Fig. 2C). The quantitative Western blot analysis (Fig. 2A) indicated
that is between 0.25-0.12% of the total Pfs48/45@PbMSP1 schizont
lysate was Pfs48/45 and therefore it is likely that the majority of the
IgG from the immunized mice is not directed against Pfs48/45. The
(caption on next page)
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failure to induce TR activity of IgG of mice immunized with WT schi-
zont lysate indicates that the small proportion of anti-Pfs48/45 anti-
bodies are mediating the TR activity after Pfs48/45@PbMSP1 schizont
lysate immunization. The strong TR activity mediated by the total IgG
isolated from Pfs48/45@PbMSP1 immunized mice (Fig. 2C), indicates
that Pfs48/45 expressed in P. berghei can induce antibodies with potent
TR activity.
Combined, our proof-of concept studies demonstrate that transgenic
Pb schizonts can be used as a system to produce a diﬃcult to express
HMP protein that is correctly folded and retains conformational epi-
topes of the native protein. This opens possibilities to use this expres-
sion system to evaluate the immunogenicity of other diﬃcult to express
antigens or speciﬁc domains of these parasites. Studies using sera ob-
tained from mice immunized with Pf proteins expressed by transgenic
Pb parasites could be used to rank-order novel vaccine candidate anti-
gens, not only in TB studies but also for blood-stage antigens using
blood stage growth inhibition assays (GIA) or sporozoite-antigens using
inhibition of sporozoite invasion (ISI) assays [3]. Moreover, the ex-
pression in transgenic schizonts of HMP proteins with aﬃnity tags will
allow for the puriﬁcation of these HMP proteins from whole parasite
lysate preparations and immunization with puriﬁed protein will mean
that all of the raised immune response is due to the target antigen and
will permit a more detailed analyses of antigen immunogenicity, for
example to examine and clone potent inhibitory and cross-reactive B-
cells/antibodies after rodent immunization [27]. The creation of
transgenic parasites that express antigens from multiple life-cycles that
can induce potent immune responses is also of interest to the devel-
opment of whole organism vaccines [28]. For example, genetically at-
tenuated sporozoite vaccines could be further modiﬁed to induce im-
mune responses against multiple life cycle stages by expression in
sporozoites and liver stages antigens of blood- or transmission–stages to
produce a multi stage-vaccine.
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